- Telehealth Visits
- Insurance plan information
R. Peter Lokken, MD, MPH
Diagnostic Radiology • Interventional Radiology- Telehealth Visits
- Insurance plan information
R. Peter Lokken, MD, MPH
Diagnostic Radiology • Interventional Radiology- Telehealth Visits
- Insurance plan information
On this page
About me
Dr. R. Peter Lokken is an interventional radiologist, an imaging specialist who uses minimally invasive techniques to treat a variety of disorders.
In his research, Lokken investigates genetic, immunological and other factors associated with outcomes for cancer patients who receive locoregional therapy, in which radiological imaging is used to guide targeted treatment of tumors. He focuses particularly on hepatocellular carcinoma (the most common type of liver cancer).
After earning a master of public health degree at the Harvard T.H. Chan School of Public Health, Lokken completed his medical degree at Harvard Medical School. He completed a residency in diagnostic radiology at Brigham and Women's Hospital, followed by a fellowship in interventional radiology at UCSF.
Before joining the UCSF faculty, Lokken was at the University of Illinois Hospital Health & Sciences System, where he specialized in vascular interventional radiology.
Lokken is an associate editor for the Journal of Vascular and Interventional Radiology, published by the Society of Interventional Radiology.
Education & training
Board certification
- Interventional and Diagnostic Radiology, American Board of Radiology
Fellowship
- Vascular & Interventional Radiology, UCSF Graduate Medical Education
Residency
- Diagnostic Radiology, Brigham and Womens Hospital GME
Internship
- Internal Medicine, University of California - San Diego
Degree
- MD, Harvard Medical School
My expertise
Specialties
My research
Publications
For informational purposes only, a link to the federal Centers for Medicare and Medicaid Services (CMS) Open Payments web page is provided here. The federal Physician Payments Sunshine Act requires that detailed information about payment and other payments of value worth over ten dollars ($10) from manufacturers of drugs, medical devices, and biologics to physicians and teaching hospitals be made available to the public.